Literature DB >> 26723110

Pathologic Response, When Increased by Longer Interval, Is a Marker but Not the Cause of Good Prognosis in Rectal Cancer: 17-year Follow-up of the Lyon R90-01 Randomized Trial.

Eddy Cotte1, Guillaume Passot2, Evelyne Decullier3, Christelle Maurice3, Olivier Glehen2, Yves François2, Fabrice Lorchel4, Olivier Chapet4, Jean-Pierre Gerard5.   

Abstract

PURPOSE: The Lyon R90-01 randomized trial investigated whether the interval between preoperative radiation therapy and surgery influenced rectal cancer outcome. Long-term results are reported here after a median follow-up of 17 years. METHODS AND MATERIALS: Between February 1991 and December 1995, 210 patients from 29 French centers were randomly assigned (ratio of 1:1) to groups that waited either 2 weeks (short interval [SI]) or 6 to 8 weeks (long interval [LI]) between neoadjuvant radiation therapy and surgery. The primary endpoint was sphincter-preserving surgery.
RESULTS: LI group showed a better pathologic response (complete response or few residual cells) after radiation therapy than the SI group (26% vs 10.3%, P=.015). A better pathologic response was associated in multivariate analysis with significant improvement of overall survival (pT: P=.0293 and pN: P=.0048) but it was irrespective of the interval duration. The median follow-up was 17.2 years. The 5-, 10-, 15-, and 17-year overall survival rates were, respectively, 66.8%, 48.7%, 40.0%, and 34.0% for the SI group and, respectively, 67.1%, 53.5%, 41.9%, and 34.0% for the LI group. There were no significant differences between groups in terms of survival (P=.7656) or local recurrence rates (SI: 14.4% vs LI: 12.1%, respectively; P=.6202). Of 24 local disease recurrences, 20 (83%) occurred during the first 2 postoperative years, and all but one (96%) occurred during the first 5 postoperative years. The rate of second new malignancies was 9.4% (19 patients).
CONCLUSIONS: The radiation-induced sterilization rate of the preoperative cancer specimen was a marker of good prognosis. The interval duration (the treatment being the same) although it is modifying the sterilization rate has no impact on survival. Radiation therapy did not postpone local recurrence, because the rate of local relapse after 5 years was low. Radiation-induced cancers after radiation therapy were unusual and should not influence treatment decisions in adults.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26723110     DOI: 10.1016/j.ijrobp.2015.10.061

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.

Authors:  Erhan Akgun; Cemil Caliskan; Osman Bozbiyik; Tayfun Yoldas; Basak Doganavsargil; Serdar Ozkok; Timur Kose; Bulent Karabulut; Nevra Elmas; Omer Ozutemiz
Journal:  BJS Open       Date:  2022-09-02

2.  How Is Rectal Cancer Managed: a Survey Exploring Current Practice Patterns in Canada.

Authors:  A Crawford; J Firtell; A Caycedo-Marulanda
Journal:  J Gastrointest Cancer       Date:  2019-06

3.  Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer.

Authors:  M Kraszkiewicz; A Napieralska; J Wydmański; R Suwiński; W Majewski
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 4.  Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy.

Authors:  Jian Cui; Hui Fang; Lin Zhang; Yun-Long Wu; Hai-Zeng Zhang
Journal:  Chronic Dis Transl Med       Date:  2016-07-28

5.  Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients.

Authors:  Gabriella Macchia; Maria Antonietta Gambacorta; Carlotta Masciocchi; Giuditta Chiloiro; Giovanna Mantello; Maika di Benedetto; Marco Lupattelli; Elisa Palazzari; Liliana Belgioia; Almalina Bacigalupo; Aldo Sainato; Sabrina Montrone; Lucia Turri; Angela Caroli; Antonino De Paoli; Fabio Matrone; Carlo Capirci; Giampaolo Montesi; Rita Marina Niespolo; Mattia Falchetto Osti; Luciana Caravatta; Alessandra Galardi; Domenico Genovesi; Maria Elena Rosetto; Caterina Boso; Piera Sciacero; Lucia Giaccherini; Salvatore Parisi; Antonella Fontana; Francesco Romeo Filippone; Vincenzo Picardi; Alessio Giuseppe Morganti; Vincenzo Valentini
Journal:  Clin Transl Radiat Oncol       Date:  2017-05-17

6.  Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis.

Authors:  Hideomi Yamashita; Soichiro Ishihara; Hiroaki Nozawa; Kazushige Kawai; Tomomichi Kiyomatsu; Kae Okuma; Osamu Abe; Toshiaki Watanabe; Keiichi Nakagawa
Journal:  Radiat Oncol       Date:  2017-09-21       Impact factor: 3.481

7.  Cross-Sectional Study on MRI Restaging After Chemoradiotherapy and Interval to Surgery in Rectal Cancer: Influence on Short- and Long-Term Outcomes.

Authors:  Robin Detering; Wernard A A Borstlap; Lisa Broeders; Linda Hermus; Corrie A M Marijnen; Regina G H Beets-Tan; Willem A Bemelman; Henderik L van Westreenen; Pieter J Tanis
Journal:  Ann Surg Oncol       Date:  2018-12-13       Impact factor: 5.344

8.  Impact of delaying surgery after chemoradiation in rectal cancer: outcomes from a tertiary cancer centre in India.

Authors:  Praveen Kammar; Aditi Chaturvedi; Masillamany Sivasanker; Ashwin de'Souza; Reena Engineer; Vikas Ostwal; Avanish Saklani
Journal:  J Gastrointest Oncol       Date:  2020-02

9.  Long-term outcomes in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy and curative resection.

Authors:  Zhao Lu; Pu Cheng; Fu Yang; Zhaoxu Zheng; Xishan Wang
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

10.  Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer.

Authors:  Richard Partl; Marton Magyar; Eva Hassler; Tanja Langsenlehner; Karin Sigrid Kapp
Journal:  Radiat Oncol       Date:  2020-05-06       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.